The Goldman Sachs Group Lowers Moderna (NASDAQ:MRNA) Price Target to $99.00

Moderna (NASDAQ:MRNA – Free Report) had its target price reduced by The Goldman Sachs Group from $112.00 to $99.00 in a report issued on Tuesday morning,Benzinga reports. They currently have a buy rating on the stock. MRNA has been the topic of a number of other reports. JPMorgan Chase & Co. dropped their price objective […]

Leave a Reply

Your email address will not be published.

Previous post Kingswood Wealth Advisors LLC Buys 2,902 Shares of Enterprise Products Partners L.P. (NYSE:EPD)
Next post Kingswood Wealth Advisors LLC Cuts Stock Holdings in iShares Silver Trust (NYSEARCA:SLV)